BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Norris V, Baisley K, Dunn K, Warrington S, Morocutti A. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers: COMBINED ANALYSIS OF RABEPRAZOLE VS. ESOMEPRAZOLE ON INTRAGASTRIC pH. Alimentary Pharmacology & Therapeutics 2007;25:501-10. [DOI: 10.1111/j.1365-2036.2006.03221.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Eggleston A, Katelaris PH, Nandurkar S, Thorpe P, Holtmann G; ON BEHALF OF THE TREAT STUDY GROUP. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care - prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. Alimentary Pharmacology & Therapeutics 2009;29:967-78. [DOI: 10.1111/j.1365-2036.2009.03948.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
2 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 14.6] [Reference Citation Analysis]
3 Koch KM, Im YH, Kim SB, Urruticoechea Ribate A, Stephenson J, Botbyl J, Cartee L, Holshouser J, Ridgway D. Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients. Clin Pharmacol Drug Dev 2013;2:336-41. [PMID: 27121938 DOI: 10.1002/cpdd.45] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hoshino S, Kawami N, Takenouchi N, Umezawa M, Hanada Y, Hoshikawa Y, Kawagoe T, Sano H, Hoshihara Y, Nomura T, Iwakiri K. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis. Digestion. 2017;95:156-161. [PMID: 28190016 DOI: 10.1159/000456072] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 9.6] [Reference Citation Analysis]
5 Bavishi C, Dupont HL. Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34:1269-1281. [PMID: 21999643 DOI: 10.1111/j.1365-2036.2011.04874.x] [Cited by in Crossref: 252] [Cited by in F6Publishing: 222] [Article Influence: 22.9] [Reference Citation Analysis]
6 Yamasaki A, Yoshio T, Muramatsu Y, Horiuchi Y, Ishiyama A, Hirasawa T, Tsuchida T, Sasaki Y, Fujisaki J. Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers. Digestion 2018;97:170-6. [PMID: 29310111 DOI: 10.1159/000485028] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
7 Liang XY, Gao Q, Gong NP, Tang LP, Wang PL, Tao XH. Comparison of esomeprazole enteric-coated capsules vs esomeprazole magnesium in the treatment of active duodenal ulcer: A randomized, double-blind, controlled study. World J Gastroenterol 2008; 14(12): 1941-1945 [PMID: 18350637 DOI: 10.3748/wjg.14.1941] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Tanabe T, Hoshino S, Kawami N, Hoshikawa Y, Hanada Y, Takenouchi N, Goto O, Kaise M, Iwakiri K. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Esophagus 2019;16:377-81. [PMID: 31119492 DOI: 10.1007/s10388-019-00676-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Masaoka T, Kameyama H, Yamane T, Yamamoto Y, Takeuchi H, Suzuki H, Kitagawa Y, Kanai T. Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test. J Neurogastroenterol Motil 2018;24:577-83. [PMID: 30347936 DOI: 10.5056/jnm18036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Furuta K, Kohata Y, Fujiwara Y, Sugimoto M, Uotani T, Yamade M, Sahara S, Ichikawa H, Furuta T, Nio K, Iwakiri R, Inamori M, Kawamura O, Kusano M, Kato M, Kawami N, Iwakiri K, Takeuchi T, Higuchi K, Aimi M, Naora K, Fujimoto K, Arakawa T, Kinoshita Y. Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison. J Clin Biochem Nutr 2014;55:178-83. [PMID: 25411523 DOI: 10.3164/jcbn.14-41] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
12 Namikoshi T, Harada K, Hatta H, Tokura T, Oshiro Y, Nishizaki T, Obata T, Mori M, Fueki T, Fujimoto S, Haruna Y, Kuwabara A, Yorimitsu D, Ihoriya C, Kadoya H, Itano S, Fujimoto Y, Komai N, Sasaki T, Kashihara N. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis. Clin Exp Nephrol 2016;20:134-42. [PMID: 26026991 DOI: 10.1007/s10157-015-1130-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
13 Umezawa M, Kawami N, Hoshino S, Hoshikawa Y, Koizumi E, Takenouchi N, Hanada Y, Kaise M, Iwakiri K. Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis. Digestion 2018;97:309-15. [PMID: 29514137 DOI: 10.1159/000485795] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
14 Yi S, Lee H, Jang SB, Byun HM, Yoon SH, Cho JY, Jang IJ, Yu KS. A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers. Aliment Pharmacol Ther 2017;46:337-46. [PMID: 28543183 DOI: 10.1111/apt.14148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
15 Liu D, Yang H, Jiang J, Nagy P, Shen K, Qian J, Hu P. Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers. J Clin Pharmacol 2016;56:816-26. [PMID: 26970404 DOI: 10.1002/jcph.733] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
16 Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65:19-31. [PMID: 18925391 DOI: 10.1007/s00228-008-0576-5] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 8.9] [Reference Citation Analysis]
17 Hoshikawa Y, Kawami N, Hoshino S, Tanabe T, Umezawa M, Kaise M, Iwakiri K. Efficacy of on-demand therapy using 20-mg vonoprazan for non-erosive reflux disease. Esophagus 2019;16:201-6. [PMID: 30600486 DOI: 10.1007/s10388-018-00654-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
18 Hunfeld NG, Touw DJ, Mathot RA, van Schaik RH, Kuipers EJ. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther. 2012;35:810-818. [PMID: 22324425 DOI: 10.1111/j.1365-2036.2012.05014.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]